Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Cash from Operations (2024 - 2025)

Caris Life Sciences has reported Cash from Operations over the past 2 years, most recently at 44780000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 44780000.0 for Q4 2025, up 215.05% from a year ago — trailing twelve months through Dec 2025 was 1143000.0 (changed N/A YoY), and the annual figure for FY2025 was 83155000.0, up 133.91%.
  • Cash from Operations for Q4 2025 was 44780000.0 at Caris Life Sciences, down from 62425000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for CAI hit a ceiling of 62425000.0 in Q3 2025 and a floor of 69427000.0 in Q3 2024.